Cargando…

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh Kumar, Gupta, Ritesh, Misra, Anoop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Diabetes India. Published by Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244409/ https://www.ncbi.nlm.nih.gov/pubmed/32473904 http://dx.doi.org/10.1016/j.dsx.2020.05.030

Ejemplares similares

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
por: Mahajan, Kunal, et al.
Publicado: (2020)

Letter in response to letter to the editor by Singh and Dhibar regarding the article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Akriti, et al.
Publicado: (2020)

Reply to the letter of Singh and Singh in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis” (Kumar et al.)
por: Kumar, Ashish, et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Reliability study of Mahajan's classification
por: Kumar, Ashish, et al.
Publicado: (2014)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Obituary: Dr. Ramesh Chander Mahajan
por: Khurana, S.
Publicado: (2022)

Letter by Mahajan Regarding Article, "A Narrow QRS Complex Tachycardia With Apparently Concentric Retrograde Atrial Activation Sequence"
por: Mahajan, Rajiv
Publicado: (2009)

Response to Singh and Singh
por: Calder, Philip C.
Publicado: (2022)

Validation of Mahajan’s formula for scaling ocular higher-order aberrations by pupil size
por: Wallace, Henry B, et al.
Publicado: (2020)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Letter to editor in response to article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Harpreet, et al.
Publicado: (2020)

Renin–Angiotensin System Implications to COVID-19 Comorbidities
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability
por: Saravi, Babak, et al.
Publicado: (2021)

Impact of Renin‐Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery
por: Antoniak, Derrick T., et al.
Publicado: (2021)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
por: Gressens, Simon B., et al.
Publicado: (2021)

Nadia Singh
por: Marwaha, Seema
Publicado: (2021)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

“The effect of vaginal and caesarean delivery on lower urinary tract symptoms: what makes the difference?”: reply to comment by Mahajan et al.
por: van Brummen, Henriette Jorien
Publicado: (2007)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k7od861ldc6l4siu0ao31qv7k8